‘Global Vaccine Contract Manufacturing Market Worth $1251m In 2021’ Says Visiongain Report

23 August 2018
Pharma

Visiongain’s new report Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies indicates that the global vaccine contract manufacturing market will see $1251m in spending in 2021.

The global vaccine contract manufacturing market is expected to grow at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. The market is expected to grow at a CAGR of 9.1% from 2016 to 2027. The market is estimated at $816m in 2016, and $2117m in 2027.
The lead analyst of the report said: “The vaccine manufacturing technology and services market has experienced considerable growth over the past decade. Vaccines are a global healthcare success, currently driven by disease burden and the expanding global population. Paediatric vaccines will continue to be the leading market segment. Strong growth will be seen in the therapeutic vaccines market, driven by development of vaccines for indications such as cancer. Our research suggests that demand and technological developments in this industry will drive changes in the methods and management of vaccine production. The global vaccine market will experience strong growth throughout the forecast period, as will that for outsourced vaccine manufacturing.
Vaccine manufacturing is highly technical with stringent regulatory and quality standards which have mainly kept it within regions which have the technology and regulatory framework to accommodate production. Although off-shoring to lower costs is very popular for other industries, the vaccine contract manufacturing market in emerging markets will mainly show growth through domestic demands, at least in the first half of the forecast period, as emerging markets still grapples with international vaccine manufacturing practises and new technology platforms.”
The 155-page report contains 74 charts that add visual analysis in order to explain the developing trends within the Global Vaccine Contract Manufacturing market.
The report provides revenue and growth forecasts to 2027 as well as qualitative analyses for the global vaccine contract manufacturing market
This report also provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the global vaccine market and market shares of the submarkets: paediatric vaccines, adult vaccines, influenza vaccines and therapeutic vaccines.

The 155-page report offers market forecasts for the United States (US), Germany, France, the United Kingdom, Italy, Spain, Japan, China, India, Brazil, Russia and Rest of the World.
The report Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies report will be of value to anyone who wants to better understand the vaccine contract manufacturing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the vaccine contract manufacturing market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever